BIIB vs QGEN
Biogen Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BIIB | QGEN |
|---|---|---|
| Revenue | $9.9B | $2.1B |
| Net income | $1.3B | $424.9M |
| Gross margin | 75.7% | 62.2% |
| Net margin | 13.1% | 20.3% |
| Return on equity | 11.0% | 11.6% |
| Diluted EPS | $8.79 | $1.94 |
| Dividend / share | — | $0.25 |
| Payout ratio | — | 12.8% |
| Free cash flow | $2.1B | $453.3M |
| Equity | $14.8B | $3.8B |
| Net debt / equity | 0.41× | 0.22× |
| Current ratio | 2.68× | 3.90× |
| Revenue CAGR 5y | −6.0% | 2.2% |
| Profit CAGR 5y | −20.2% | 3.4% |
BIIB bills 4.7× the revenue of QGEN, and QGEN keeps more of each dollar of revenue as profit (20.3% against 13.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | BIIB | QGEN |
|---|---|---|
| FY2025 | $9.9B | $2.1B |
| FY2024 | $9.7B | $2.0B |
| FY2023 | $9.8B | $2.0B |
| FY2022 | $10.2B | $2.1B |
| FY2021 | $11.0B | $2.3B |
| FY2020 | $13.4B | $1.9B |
| FY2019 | $14.4B | $1.5B |
| FY2018 | $13.5B | $1.5B |
| FY2017 | $12.3B | $1.4B |
| FY2016 | $11.4B | $1.3B |
Net income by year
Bottom line
| Fiscal year | BIIB | QGEN |
|---|---|---|
| FY2025 | $1.3B | $424.9M |
| FY2024 | $1.6B | $83.6M |
| FY2023 | $1.2B | $341.3M |
| FY2022 | $3.0B | $423.2M |
| FY2021 | $1.6B | $512.6M |
| FY2020 | $4.0B | $359.2M |
| FY2019 | $5.9B | $-41.5M |
| FY2018 | $4.4B | $190.4M |
| FY2017 | $2.5B | $40.4M |
| FY2016 | $3.7B | $80.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry